AEZS News Alert Aeterna Zentaris (AEZS) 0.62 12/17/2014 00:2

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Aeterna Zentaris (AEZS) 0.62 $AEZS

INVESTOR ALERT: Class Action Lawsuit Against Aeterna Zentaris Inc. Announced by Law Offices of Howard G. Smith
Business Wire - Tue Dec 16, 9:32AM CST
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey on behalf of purchasers of the securities of Aeterna Zentaris Inc. ("Aeterna" or the "Company" (NASDAQ:AEZS) between October 18, 2012 and November 5, 2014, inclusive (the "Class Period" . Aeterna is a specialty biopharmaceutical company, and is developing macimorelin a^' an orally active small molecule that stimulates the secretion of growth hormone a^' as a treatment for Adult Growth Hormone Deficiency.
AEZS: 0.62 (+0.01)

SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Notifies Investors of Class Action Against Aeterna Zentaris Inc. and Its Board of Directors and a Lead Plaintiff Deadline of January 12, 2015 -- AEZS
GlobeNewswire - Thu Dec 11, 3:10PM CST
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of investors who purchased Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company" (Nasdaq:AEZS) securities between October 18, 2012 and November 5, 2014.
AEZS: 0.62 (+0.01)

INVESTOR ALERT: Glancy Binkow & Goldberg LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Lawsuit Against Aeterna Zentaris Inc.
Business Wire - Thu Dec 11, 12:42PM CST
Glancy Binkow & Goldberg LLP reminds investors of Aeterna Zentaris Inc. ("Aeterna" or the "Company" (NASDAQ:AEZS) that purchasers of Aeterna securities between October 18, 2012 and November 5, 2014, inclusive (the "Class Period" , have until January 12, 2015, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit filed in the United States District Court for the District of New Jersey.
AEZS: 0.62 (+0.01)

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From Investment in Aeterna Zentaris, Inc. to Contact Brower Piven Before the January 12, 2015 Lead Plaintiff Deadline in Class Action Lawsuit -- AEZS
GlobeNewswire - Tue Dec 09, 9:10PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Aeterna Zentaris, Inc. ("Aeterna Zentaris" or the "Company" (Nasdaq:AEZS) securities during the period between October 18, 2012 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 12, 2015 to seek appointment as lead plaintiff.
AEZS: 0.62 (+0.01)

Update: My Discussion With RedChip And Thoughts Going Forward
Daniel Ward - at Seeking Alpha - Mon Dec 08, 8:08AM CST

XBI: 174.87 (-1.02), AKER: 2.99 (+0.01), AEZS: 0.62 (+0.01)

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on Their Investment in Aeterna Zentaris, Inc. of Class Action Lawsuit and Upcoming Deadline -- AEZS
GlobeNewswire - Fri Dec 05, 1:40PM CST
Pomerantz LLP has filed a class action lawsuit against Aeterna Zentaris, Inc. ("Aeterna" or the "Company" (Nasdaq:AEZS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased Aeterna securities between June 26, 2012 and November 5, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
AEZS: 0.62 (+0.01)

Cancer Cachexia - Pipeline Review, H2 2014
M2 - Wed Dec 03, 7:39AM CST
Research and Markets (http://www.researchandmarkets.com/research/nngtcd/cancer_cachexia) has announced the addition of the "Cancer Cachexia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Cancer Cachexia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Cancer Cachexia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Cancer Cachexia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Cancer Cachexia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Amgen - Eli Lilly and Company - Novartis - Aphios - GTx - Incyte - AEterna Zentaris - Helsinn Healthcare - Radius Health - Vicus Therapeutics - Ohr Pharmaceutical - KAEL-GemVax - RaQualia Pharma - Acacia Pharma - PsiOxus Therapeutics - Signablok - Myomics For more information visit http://www.researchandmarkets.com/research/nn...r_cachexia
RDUS: 26.30 (+1.20), AMGN: 159.44 (-0.16), AEZS: 0.62 (+0.01), OHRP: 7.93 (-0.22), LLY: 69.26 (-0.41), NVS: 91.65 (+0.01)

Aeterna Zentaris adds to up move
Seeking Alpha - at Seeking Alpha - Tue Dec 02, 12:05PM CST

AEZS: 0.62 (+0.01)

Stock to Watch: AEterna Zentaris Up 16.9% (AEZS)
Comtex SmarTrend(R) - Mon Dec 01, 11:36AM CST
AEterna Zentaris (NASDAQ:AEZS) is one of today's best performing penny stocks, up 16.9% to $0.61 on 1.1x average daily volume. AEterna Zentaris has traded 2.9 million shares thus far today, vs. average volume of 2.8 million shares per day. The stock has outperformed the Dow (16.9% to the Dow's -0.3%) and outperformed the S&P 500 (16.9% to the S&P's -0.7%) during today's trading.
AEZS: 0.62 (+0.01)

Aeterna Zentaris and Sinopharm A-Think Sign Master Collaboration Agreement for Zoptarelin Doxorubicin in China
PR Newswire - Mon Dec 01, 6:30AM CST
All amounts are in U.S. dollars
AEZ.TO: 0.74 (+0.02), AEZS: 0.62 (+0.01)

EQUITY ALERT: Rosen Law Firm Reminds Aeterna Zentaris, Inc. Investors of Important Deadline in Class Action Filed by the Firm -- AEZS
GlobeNewswire - Fri Nov 28, 5:45PM CST
Rosen Law Firm reminds purchasers of Aeterna Zentaris, Inc. securities (Nasdaq:AEZS) between October 18, 2012 and November 6, 2014 of the important January 12, 2015 lead plaintiff deadline in the class action filed by the firm.
AEZS: 0.62 (+0.01)

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Aeterna Zentaris, Inc. To Contact Brower Piven Before The January 12, 2015 Lead Plaintiff Deadline In Class Action Lawsuit
Business Wire - Tue Nov 25, 5:15PM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of New Jersey on behalf of purchasers of Aeterna Zentaris, Inc. ("Aeterna Zentaris" or the "Company" (Nasdaq: AEZS) securities during the period between October 18, 2012 and November 6, 2014, inclusive (the "Class Period" . Investors who wish to become proactively involved in the litigation have until January 12, 2015 to seek appointment as lead plaintiff.
AEZS: 0.62 (+0.01)

Robbins Arroyo LLP: Aeterna Zentaris Inc. (AEZS) Misled Shareholders According to a Recently Filed Class Action
GlobeNewswire - Tue Nov 25, 5:04PM CST
Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Aeterna Zentaris Inc. (Nasdaq:AEZS) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey. The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between October 18, 2012 and November 5, 2014. Aeterna Zentaris is a specialty biopharmaceutical company that develops and commercializes novel treatments in oncology and endocrinology.
AEZS: 0.62 (+0.01)

INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Aeterna Zentaris Inc. (AEZS) to Contact the Firm
Marketwired - Fri Nov 21, 7:20PM CST
Faruqi & Faruqi, LLP, a leading national securities law firm, notifies investors of the class action lawsuit filed against Aeterna Zentaris Inc. ("Aeterna" or the "Company" (NASDAQ: AEZS) in the United States District Court for the District of New Jersey.
AEZS: 0.62 (+0.01)

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Aeterna Zentaris, Inc. and Certain Officers -- AEZS
GlobeNewswire - Fri Nov 21, 4:16PM CST
Pomerantz LLP has filed a class action lawsuit against Aeterna Zentaris, Inc. ("Aeterna" or the "Company" (Nasdaq:AEZS) and certain of its officers. The class action, filed in United States District Court, District of New Jersey, is on behalf of a class consisting of all persons or entities who purchased Aeterna securities between June 26, 2012 and November 5, 2014, inclusive (the "Class Period" . This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the "Exchange Act" .
AEZS: 0.62 (+0.01)

SHAREHOLDER ALERT: Class Action Lawsuit Against Aeterna Zentaris Inc. Filed By Glancy Binkow & Goldberg LLP
Business Wire - Fri Nov 21, 11:32AM CST
Glancy Binkow & Goldberg LLP, representing investors of Aeterna Zentaris Inc. ("Aeterna" or the "Company" (NASDAQ:AEZS), has filed a class action lawsuit in the United States District Court for the District of New Jersey on behalf of a class (the "Class" comprising purchasers of Aeterna securities between October 18, 2012 and November 5, 2014, inclusive (the "Class Period" .
AEZS: 0.62 (+0.01)

Aeterna Zentaris Adds Hollings Cancer Center to Multi-National Phase 3 Trial in Endometrial Cancer
PR Newswire - Thu Nov 20, 6:30AM CST
Patient recruitment in line to secure expected interim analysis in H1 2015
AEZ.TO: 0.74 (+0.02), AEZS: 0.62 (+0.01)

Notice of Filing of Securities Fraud Class Action against Aeterna Zentaris Inc. by Abraham, Fruchter & Twersky, LLP
Business Wire - Mon Nov 17, 9:33AM CST
Abraham, Fruchter & Twersky, LLP has filed a securities fraud class action against Aeterna Zentaris Inc. ("Aeterna Zentaris" or the "Company" (NASDAQ:AEZS) and certain of its senior executives in the United States District Court for the District of New Jersey (the "Court" .
AEZS: 0.62 (+0.01)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
Chord's $550 Million Exit Tightens Its Basin Focus

Updated Category News Views 83

One map pin just disappeared from Chord Energy’s corporate wall, and that matters more than the usual deal-closing confetti. Chord has completed the sale of its entire non-operated Marcellus position to POSCO International for $550 million in gross consideration. For shareholders in NASDAQ:CHRD, this is not a flashy new drilling story. It is a cleanup job, and sometimes...

Continue Reading
AMD Faces Fresh Scrutiny Over China Supply Exposure

Updated Category News Views 140

One nasty report can turn a chip giant’s supply chain into a flashing red light, and that is precisely the mess confronting Advanced Micro Devices investors this week. Shares fell more than 7.7% on November 19 after Hunterbrook Media published allegations involving China-linked sales, firmware and manufacturing relationships. Then, on November 20, shareholder-rights...

Continue Reading
Allooloo's 100M Calls Test Capital Markets AI Data

Updated Category News Views 160

Forty-one point nine thousand issuers is a lot of financial clutter to keep straight, and Allooloo says its machines are getting called on to do precisely that at industrial scale. The Vancouver-based company reported on November 20 that its capital-markets data products now receive 100 million AI-agent calls a month—roughly 3.4 million daily, or 39 per second. That is...

Continue Reading
ASU's International Enrollment Lead Carries Real Weight

Updated Category News Views 125

Twenty thousand nine hundred twenty-six international students is not a campus footnote; it is a serious operating force moving through Arizona State University and the state around it. ASU has held the No. 1 spot among U.S. public universities hosting international students for six straight years, and the 2026 Open Doors report puts it No. 2 across public and private...

Continue Reading
S&P Global's December 8 Talk Puts Guidance in Focus

Updated Category News Views 71

A 35-minute fireside chat can be a whole lot of nothing, or it can leave a useful breadcrumb trail for shareholders willing to listen closely. S&P Global has put December 8, 2026 on the calendar, when Chief Executive Officer Martina Cheung is scheduled to appear at Goldman Sachs' 2026 Financial Services Conference in New York. Her slot runs from 5:00 p.m. to 5:35 p.m....

Continue Reading
Midterm Voters Put Cost Relief Ahead of Washington Wars

Updated Category News Views 100

Gas pumps and medical bills have a way of humiliating every grand political slogan ever printed. Seven Letter Insight's latest post-election survey says confirmed 2026 midterm voters want the 120th Congress to deal with costs first, particularly gas prices, health care, restoring health care tax credits and energy bills. That is not a glamorous mandate. It is, however,...

Continue Reading
Domino's Probe Puts Franchise Disclosure Under Lens

Updated Category News Views 110

A franchisee's shuttered stores can turn cheerful unit-growth talk into a nasty accounting of credibility, and that is the uncomfortable territory Domino's now occupies. Kahn Swick & Foti has opened an investigation into whether Domino's officers and directors breached fiduciary duties or violated state or federal law. That is not a finding of misconduct. It is a legal...

Continue Reading
Alibaba Lawsuit Deadline Puts Disclosure Risk in Focus

Updated Category News Views 169

A calendar deadline is doing more work than any earnings headline for Alibaba shareholders this week. A securities class action notice says investors who bought or acquired Alibaba Group Holding Limited securities between May 23, 2024 and November 11, 2026 may seek appointment as lead plaintiff by January 19, 2027. That is a procedural milestone, not a verdict, and...

Continue Reading
ModuleMD Takes Allergy EHR AI Beyond the Usual Hype Cycle

Updated Category News Views 84

Allergy Workflows Are Where This Has to Earn Its Keep Allergy clinics do not need another shiny dashboard clogging up a workstation. They need less typing, fewer handoffs, cleaner documentation, and fewer administrative chores slipping through the cracks while a packed day keeps moving. That is the practical lens for ModuleMD's ACAAI 2026 presentation in Phoenix: not...

Continue Reading

Top 5 Most Recently Viewed Articles

Exciting Funding Opportunity for Cartier Silver Corporation

Updated Category News Views 136

Cartier Silver Corporation Announces Financing Initiative Cartier Silver Corporation (CSE: CFE) has exciting news that emphasizes its commitment to growth and exploration. The Company is moving forward with a non-brokered private placement, intending to raise up to $1.5 million. Details of the Private Placement Under the terms of this Private Placement, Cartier Silver...

Continue Reading
Dynex Capital, Inc. Announces Exciting Dividend Updates

Updated Category News Views 56

Dynex Capital, Inc. Dividend Updates Dynex Capital, Inc. has recently made some important announcements regarding its dividends. The Board of Directors declared a cash dividend of $0.13 per share on its Common Stock (NYSE: DX) for September. Additionally, they revealed a quarterly cash dividend of $0.43125 per share for the 6.900% Series C Fixed-to-Floating Rate...

Continue Reading
Innovative Detox Solution to Alleviate Pain and Stress

Updated Category News Views 163

Introducing an Innovative Detox Solution In a world where wellness and self-care are becoming increasingly essential, an inventive product named TREETOX has emerged, aiming to redefine the way we think about detoxification and pain relief. Invented by a visionary in Pittsburgh, this product presents a seamless alternative for individuals battling ADHD and autism who are...

Continue Reading
WesBanco, Inc. Appoints Amby Bauer as Market President

Updated Category News Views 174

WesBanco, Inc. Names Amby Bauer as Western Pennsylvania Market President WesBanco, Inc. (NASDAQ: WSBC), a prominent multi-state banking institution, has announced the appointment of Amby Bauer as the new Western Pennsylvania Market President and Senior Commercial Banker. This strategic move comes at a time when the bank is focusing on enhancing its service provisions in...

Continue Reading
Svitzer Group Reports Major Shareholder Update from Morgan Stanley

Updated Category News Views 268

Svitzer Group Announces Major Shareholder Update In a significant development, Svitzer Group A/S has received a noteworthy notification concerning major shareholder dealings. The global leader in towage and marine services, Svitzer Group, confirmed a recent communication from Morgan Stanley regarding their shareholdings. As of a specified date, Morgan Stanley reportedly...

Continue Reading